Analysis demonstrates semaglutide is safe and effective in patients with chronic kidney disease both with and without diabetes, showing kidney-protective benefits alongside metabolic improvements.
Safe in CKDSemaglutide demonstrated safety and kidney-protective benefits in chronic kidney disease patients both with and without diabetes
What the researchers found
Semaglutide demonstrated safety and efficacy in CKD patients with and without diabetes, showing metabolic benefits and kidney-protective effects in this high-risk population.
Why it matters
CKD patients have the highest cardiovascular risk and limited treatment options. Confirming semaglutide is safe and beneficial in CKD expands its use to a population that needs it most.
The numbers in context
Over 500 million people globally have chronic kidney disease. This meta-analysis included both diabetic and non-diabetic CKD populations.
How the study worked
Analysis of semaglutide safety and efficacy data in patients with chronic kidney disease, comparing outcomes in diabetic and non-diabetic CKD populations.
Who was studied
Chronic kidney disease patients with and without type 2 diabetes
What this study cannot tell us
Analysis details not fully available from abstract. CKD severity stages and specific kidney outcomes need examination. Drug dosing may need adjustment in severe CKD.
How to read the evidence
Strong evidence: analysis of clinical data in CKD populations, building on the FLOW trial evidence for semaglutide kidney protection.
When this study was published
Published in 2025. Extends semaglutide CKD evidence beyond the diabetic nephropathy focus of the FLOW trial.
The bigger picture
GLP-1 drugs are emerging as kidney-protective agents alongside their metabolic benefits. The FLOW trial showed semaglutide slows CKD progression in diabetic nephropathy. This analysis extends the evidence to broader CKD populations, potentially making semaglutide standard care for kidney disease patients.
Questions still open
- At what CKD stage should semaglutide be initiated for optimal kidney protection?
- Does semaglutide benefit CKD patients who are not overweight?
- Should semaglutide become first-line therapy for all CKD patients?
Common questions
Can I take semaglutide with kidney disease?
Does semaglutide protect the kidneys?
Read the original research
Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Endocrinology, diabetes & metabolism, 8(6), e70136
Citation
Abdullah, Ali; Sagreeka, F N U; Aniket, Gurdas Alias; Lal, Rohan; Geeta, F N U; Bai, Anusha; Ahmed, Ghazi Uddin; Raza, Ahmed Asad; Shaikh, Varisha Fatima; Sanaullah, Owais; Sabahat, Syeda Elezeh; Ghori, Ahzam Khan; Bhutto, Seema Habib; Tesfaye, Mahir. (2025). Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis.. Endocrinology, diabetes & metabolism, 8(6), e70136. https://doi.org/10.1002/edm2.70136